Who are Pegyinterferon-alfa-2a's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PegIFN-2b, PegIFN alfa-2a, PEG -Intron, Rosiglitazone and Pegasys/Ribavirin, Pegylated-Proline-interferon alpha-2b, Peginterferon alfa-2b (PEG).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pegyinterferon-alfa-2a.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Pegyinterferon-alfa-2a — Competitive Intelligence Brief

Pegyinterferon-alfa-2a (Pegyinterferon-alfa-2a) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pegylated interferon. Area: Virology, Oncology.

marketed Pegylated interferon Interferon-alfa receptor (IFNAR) Virology, Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Pegyinterferon-alfa-2a (Pegyinterferon-alfa-2a) — Chinese University of Hong Kong. Pegyinterferon-alfa-2a is a pegylated form of interferon-alfa that activates innate immune responses to suppress viral replication and inhibit cell proliferation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Pegyinterferon-alfa-2a TARGET	Pegyinterferon-alfa-2a	Chinese University of Hong Kong	marketed	Pegylated interferon	Interferon-alfa receptor (IFNAR)
PegIFN-2b	PegIFN-2b	Merck Sharp & Dohme LLC	marketed	Pegylated interferon-beta	Interferon-beta receptor (IFNAR)
PegIFN alfa-2a	PegIFN alfa-2a	The Second Affiliated Hospital of Chongqing Medical University	marketed	Pegylated interferon alpha	Interferon-alpha receptor (IFNAR)
PEG -Intron	PEG -Intron	Beth Israel Deaconess Medical Center	marketed	Pegylated interferon alfa	Interferon-alpha receptor (IFNAR)
Rosiglitazone and Pegasys/Ribavirin	Rosiglitazone and Pegasys/Ribavirin	Beth Israel Medical Center	marketed	Thiazolidinedione (rosiglitazone) combined with pegylated interferon alfa-2a and nucleoside analog (ribavirin)	PPAR-γ (rosiglitazone); Interferon-α receptor and HCV NS5B polymerase (pegasys/ribavirin)
Pegylated-Proline-interferon alpha-2b	Pegylated-Proline-interferon alpha-2b	AOP Orphan Pharmaceuticals AG	phase 3	Pegylated interferon alpha	Interferon-alpha receptor (IFNAR)
Peginterferon alfa-2b (PEG)	Peginterferon alfa-2b (PEG)	Merck Sharp & Dohme LLC	phase 3	Pegylated interferon alfa	Interferon-alpha receptor (IFNAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pegylated interferon class)

Chinese University of Hong Kong · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pegyinterferon-alfa-2a — Competitive Intelligence Brief. https://druglandscape.com/ci/pegyinterferon-alfa-2a. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab